Bristol Myers: trial results in schizophrenia

(CercleFinance.com) - Bristol Myers Squibb has announced new top-line results from the open-label Phase 3 EMERGENT-4 and EMERGENT-5 trials evaluating the long-term efficacy, safety and tolerability of COBENFY (xanomeline trospium chloride) in adults with schizophrenia over 52 weeks of treatment.


The data was presented at Psych Congress 2024, held from 29 October to 2 November 2024 in Boston, Massachusetts.

EMERGENT-4 was a 52-week, open-label, outpatient, Phase 3 extension study evaluating the long-term safety, tolerability and efficacy of COBENFY in 156 adults with schizophrenia who had previously completed the treatment period of one of the Phase 3, five-week, double-blind, placebo-controlled efficacy and safety studies, EMERGENT-2 or EMERGENT-3.

The results of our long-term trials further support the differentiated profile of COBENFY and reinforce previous findings of robust and sustained symptom reduction with long-term treatment, Bristol Myers Squibb said.

We are pleased to see a compelling safety and tolerability profile associated with long-term treatment with COBENFY, which is consistent with previous studies. With COBENFY now available for adults with schizophrenia, we look forward to better understanding the true impact of this differentiated treatment option.


Copyright (c) 2024 CercleFinance.com. All rights reserved.